Based on EMPA-REG OUTCOME data, the European Commission has for the first time approved an agent against type 2 diabetes, empagliflozin, to both lower blood glucose and the risk of CV events.
Rivaroxaban significantly reduced CV events in patients with coronary or peripheral disease in COMPASS trial
In a meta-analysis with more than 5 000 patients with a median alirocumab exposure of 1.5 years, low levels of LDL-C (<25 mg/dl) were associated with an increased incidence of cataracts.
After 49 years follow-up, the HBS study found that high cholesterol levels predict Alzheimer disease with atherosclerotic vascular disease (ASCVD), but not without ASCVD or with vascular dementia.
Irregular eating patterns appear less favourable for maintaining body weight and optimal cardiometabolic health.
Alirocumab treatment of healthy volunteers reduced LDL-C and LDL-apoB concentrations and doubled the efficiency with which LDL particles were removed from the circulation.
The evolocumab EBBINGHAUS trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.
Evolocumab CV outcomes study meets primary and key secondary endpoints, showing reduced risk of CV events in those with ASCVD already on optimised statin therapy.
10% sodium intake reduction over 10 years achieved by education, government and industry regulations was estimated to be most cost effective in all and extremely cost effective in nearly all of 183 nations evaluated.
Depression and exhaustion predict lower life expectancy and higher CVD mortality risk with an effect size comparable to traditional major risk factors.
Although crude triglyceride response after a meal was associated with difference in carotid intima media thickness, this association was lost after correction for age, sex and fasting triglycerides.
In a large population of young males who were followed-up for 22 years, non-HDL-C was a more potent predictor of CVD mortality than LDL-C.